These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 7528477)

  • 1. Dermatofibroma and dermatofibrosarcoma protuberans: differential expression of CD34 and factor XIIIa.
    Cohen PR; Rapin RP; Farhood AI
    Am J Dermatopathol; 1994 Oct; 16(5):573-4. PubMed ID: 7528477
    [No Abstract]   [Full Text] [Related]  

  • 2. CD34 and factor XIIIa in the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans.
    Abenoza P; Lillemoe T
    Am J Dermatopathol; 1993 Oct; 15(5):429-34. PubMed ID: 7694515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tenascin differentiates dermatofibroma from dermatofibrosarcoma protuberans: comparison with CD34 and factor XIIIa.
    Kahn HJ; Fekete E; From L
    Hum Pathol; 2001 Jan; 32(1):50-6. PubMed ID: 11172295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD34 and factor-XIIIa immunoreactivity in dermatofibrosarcoma protuberans and dermatofibroma.
    Goldblum JR; Tuthill RJ
    Am J Dermatopathol; 1997 Apr; 19(2):147-53. PubMed ID: 9129699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atrophic variants of dermatofibroma and dermatofibrosarcoma protuberans.
    Zelger BW; Ofner D; Zelger BG
    Histopathology; 1995 Jun; 26(6):519-27. PubMed ID: 7545142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. When Immunohistochemistry Deceives Us: The Pitfalls of CD34 and Factor XIIIa Stains in Dermatofibroma and Dermatofibrosarcoma Protuberans.
    John AM; Holahan HH; Singh P; Handler MZ; Lambert WC
    Skinmed; 2017; 15(1):53-55. PubMed ID: 28270311
    [No Abstract]   [Full Text] [Related]  

  • 7. Differential expression of HMGA1 and HMGA2 in dermatofibroma and dermatofibrosarcoma protuberans: potential diagnostic applications, and comparison with histologic findings, CD34, and factor XIIIa immunoreactivity.
    Li N; McNiff J; Hui P; Manfioletti G; Tallini G
    Am J Dermatopathol; 2004 Aug; 26(4):267-72. PubMed ID: 15249855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High proliferative activity excludes dermatofibroma: report of the utility of MIB-1 in the differential diagnosis of selected fibrohistiocytic tumors.
    Hanly AJ; Jordà M; Elgart GW; Badiavas E; Nassiri M; Nadji M
    Arch Pathol Lab Med; 2006 Jun; 130(6):831-4. PubMed ID: 16740036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of CD163 in dermatofibroma, cellular fibrous histiocytoma, and dermatofibrosarcoma protuberans: comparison with CD68, CD34, and Factor XIIIa.
    Sachdev R; Sundram U
    J Cutan Pathol; 2006 May; 33(5):353-60. PubMed ID: 16640542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD34-positive myxoid dermatofibrohistiocytoma of the skin: an indolent post-traumatic tumor that can be mistaken for dermatofibrosarcoma protuberans.
    Al-Quran SZ; Russo JJ; Bandarchi-Chamkhaleh B; Hassanein AM
    J Cutan Pathol; 2009 Jan; 36(1):84-6. PubMed ID: 19125740
    [No Abstract]   [Full Text] [Related]  

  • 11. Expression of nestin in dermatofibrosarcoma protuberans in comparison to dermatofibroma.
    Mori T; Misago N; Yamamoto O; Toda S; Narisawa Y
    J Dermatol; 2008 Jul; 35(7):419-25. PubMed ID: 18705829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Differences of the molecular phenotypes and the histogenesis between dermatofibroma and dermatofibrosarcoma protuberans].
    Xiong Y; Guo H; Zhang S; Zhang B; Li T
    Beijing Da Xue Xue Bao Yi Xue Ban; 2008 Aug; 40(4):395-400. PubMed ID: 18677387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pathological distinction between "deep penetrating" dermatofibroma and dermatofibrosarcoma protuberans.
    Wick MR; Ritter JH; Lind AC; Swanson PE
    Semin Cutan Med Surg; 1999 Mar; 18(1):91-8. PubMed ID: 10188848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A study of CD117 expression in dermatofibrosarcoma protuberans and cellular dermatofibroma.
    Labonte S; Hanna W; Bandarchi-Chamkhaleh B
    J Cutan Pathol; 2007 Nov; 34(11):857-60. PubMed ID: 17944726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular fibrous histiocytoma of the skin: evidence of a clonal process with different karyotype from dermatofibrosarcoma.
    Vanni R; Marras S; Faa G; Licheri S; Daniele GM; Fletcher CD
    Genes Chromosomes Cancer; 1997 Apr; 18(4):314-7. PubMed ID: 9087573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COL1A1:PDGFB chimeric transcripts are not present in indeterminate fibrohistiocytic lesions of the skin.
    Wang WL; Patel KU; Coleman NM; Smith-Zagone MJ; Ivan D; Reed JA; López-Terrada D; Lazar AJ; Prieto VG
    Am J Dermatopathol; 2010 Apr; 32(2):149-53. PubMed ID: 19940748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Indeterminate fibrohistiocytic lesions of the skin: is there a spectrum between dermatofibroma and dermatofibrosarcoma protuberans?
    Horenstein MG; Prieto VG; Nuckols JD; Burchette JL; Shea CR
    Am J Surg Pathol; 2000 Jul; 24(7):996-1003. PubMed ID: 10895822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tenascin expression in cutaneous fibrohistiocytic tumors. Immunohistochemical investigation of 24 cases.
    Franchi A; Santucci M
    Am J Dermatopathol; 1996 Oct; 18(5):454-9. PubMed ID: 8902090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Fibrohistiocytic tumors of the skin: a heterogeneous group of superficially located mesenchymal neoplasms].
    Mentzel T
    Pathologe; 2015 Feb; 36(1):79-88. PubMed ID: 25589356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD44 and hyaluronate in the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans.
    Calikoglu E; Augsburger E; Chavaz P; Saurat JH; Kaya G
    J Cutan Pathol; 2003 Mar; 30(3):185-9. PubMed ID: 12641778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.